(19)
(11) EP 3 492 477 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
18.10.2023 Bulletin 2023/42

(45) Mention of the grant of the patent:
06.09.2023 Bulletin 2023/36

(21) Application number: 17834146.7

(22) Date of filing: 20.07.2017
(51) International Patent Classification (IPC): 
C07F 5/05(2006.01)
A61K 31/69(2006.01)
A61P 35/00(2006.01)
C07H 23/00(2006.01)
A61K 41/00(2020.01)
(52) Cooperative Patent Classification (CPC):
A61K 41/00; A61K 31/69; A61P 35/00; C07F 5/05; C07H 23/00
(86) International application number:
PCT/JP2017/026272
(87) International publication number:
WO 2018/021138 (01.02.2018 Gazette 2018/05)

(54)

BORON-CONTAINING COMPOUND

BORHALTIGE VERBINDUNG

COMPOSÉ CONTENANT DU BORE


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 28.07.2016 JP 2016148978

(43) Date of publication of application:
05.06.2019 Bulletin 2019/23

(73) Proprietors:
  • Stella Pharma Corporation
    Osaka-shi, Osaka 541-0043 (JP)
  • University Public Corporation Osaka
    Osaka-shi, Osaka 545-0051 (JP)

(72) Inventors:
  • HATTORI, Yoshihide
    Sakai-shi Osaka 599-8531 (JP)
  • UEHARA, Kohki
    Osaka-shi Osaka 541-0043 (JP)
  • KIRIHATA, Mitsunori
    Sakai-shi Osaka 599-8531 (JP)

(74) Representative: Cabinet Beau de Loménie 
158, rue de l'Université
75340 Paris Cedex 07
75340 Paris Cedex 07 (FR)


(56) References cited: : 
EP-A1- 2 319 849
WO-A1-2007/097065
WO-A1-2010/010913
JP-A- H02 207 086
JP-A- 2009 504 732
EP-A1- 2 602 261
WO-A1-2010/010912
WO-A1-2012/018015
JP-A- 2009 067 777
JP-A- 2012 153 647
   
  • YOSHIHIDE HATTORI ET AL: "-Amino Acids for Boron Neutron Capture Therapy", JOURNAL OF MEDICINAL CHEMISTRY, vol. 55, no. 15, 24 July 2012 (2012-07-24) , pages 6980-6984, XP055671906, US ISSN: 0022-2623, DOI: 10.1021/jm300749q
  • R. F. BARTH: "Boron Neutron Capture Therapy of Cancer: Current Status and Future Prospects", CLINICAL CANCER RESEARCH, vol. 11, no. 11, 1 June 2005 (2005-06-01), pages 3987-4002, XP055554703, US ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-05-0035
  • ANDREW G DOUGLASS ET AL: "A versatile monomer for polyelectrolytes via ROMP", POLYMER PREPRINTS, vol. 37, no. 1, 1 January 1996 (1996-01-01), page 634, XP055671919,
  • GENADY, AFAF R. ET AL.: 'Undecahydro-closo-dodecaborates as good leaving groups in organic synthesis: generation of substituted styrenes via elimination of arylethyl dodecaborates' ORGANIC & BIOMOLECULAR CHEMISTRY vol. 8, no. 19, 07 October 2010, pages 4427 - 4435, XP055459199
  • JUSTUS, EUGEN ET AL.: 'Preparation of Carboranyl and Dodecaborate Derivatives of Coumarin' COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS vol. 72, no. 12, 2007, pages 1740 - 1754, XP055459208
  • YISGEDU, TESHOME B. ET AL.: 'Synthesis and Characterization of Homopolymers and Copolymers Containing closo-[B12H12]2? Boron Cage Derivatives' CHEMISTRY A EUROPEAN JOURNAL vol. 15, no. 9, 16 February 2009, pages 2190 - 2199, XP055459213
  • HARFST, SVEN ET AL.: 'Reversed-phase separation of ionic organoborate clusters by high-performance liquid chromatography' JOURNAL OF CHROMATOGRAPHY A vol. 678, no. 1, 26 August 1994, pages 41 - 48, XP026503409
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).